secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001213900-25-021205
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt settles Aldevron dispute with $1.8M; Adimune ships ADI-100 drug substances
--------------------------------------------------------------------------------

- Settlement with Aldevron: pays $1M cash and issues $824,371.06 promissory note due May 16, 2025, with 1.5% interest if unpaid.
- Adimune subsidiary begins shipment of GMP clinical-grade drug substances for final formulation of ADI-100.
- Preclinical data: no toxicity, no antibody formation, no organ persistence; immune system not impaired.
- Clinical trials planned in Germany (psoriasis, Type 1 Diabetes) and at Mayo Clinic (Stiff Person Syndrome).
- Pre-IND meeting with FDA expected Q2 2025; German regulatory pre-submission meetings completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025021205/0001213900-25-021205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390025021205/ea0233377-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-021205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer